When to Order Imaging for Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: ACR Appropriateness Decoded

When to Order Imaging for Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: ACR Appropriateness Decoded

A 65-year-old male presents with an elevated prostate-specific antigen (PSA) level and a concerning digital rectal exam. You suspect prostate cancer, but the next step in the diagnostic and staging pathway is critical. Do you proceed directly to biopsy, or is imaging warranted first? If so, which modality—MRI, CT, or a nuclear medicine study? Choosing the correct initial and subsequent imaging studies is essential for accurate diagnosis, risk stratification, and treatment planning, while avoiding unnecessary radiation and cost. Here’s a breakdown of how the American College of Radiology (ACR) Appropriateness Criteria guide these decisions for the pretreatment detection, surveillance, and staging of prostate cancer.

What Does ACR Pretreatment Detection, Surveillance, and Staging of Prostate Cancer Cover?

This ACR guideline focuses on the role of imaging in several key clinical scenarios involving prostate cancer before definitive treatment. The recommendations address the initial workup of patients with suspected cancer (biopsy-naïve), the evaluation of patients with a prior negative biopsy but ongoing suspicion, the monitoring of patients on active surveillance for low-risk disease, and the initial staging of patients with newly diagnosed intermediate- and high-risk cancer. The criteria are designed to guide the selection of the most appropriate imaging modality to detect clinically significant disease, assess local extent, and evaluate for nodal and distant metastatic spread. These guidelines do not cover imaging for post-treatment surveillance (e.g., biochemical recurrence), screening in the general population, or the evaluation of non-cancerous prostate conditions like benign prostatic hyperplasia (BPH) or prostatitis.

What Imaging Should I Order for Pretreatment Detection, Surveillance, and Staging of Prostate Cancer? Recommendations by Clinical Scenario

Imaging for prostate cancer is highly dependent on the specific clinical context, from initial suspicion to staging of high-risk disease. The ACR provides clear, evidence-based recommendations for each step.

For a patient who is biopsy-naïve with clinically suspected prostate cancer, or for a patient with ongoing suspicion after a negative TRUS-guided biopsy, multiparametric MRI of the pelvis is a cornerstone. The ACR rates MRI pelvis without and with IV contrast and MRI pelvis without IV contrast as Usually Appropriate. This imaging helps identify and localize suspicious lesions, guiding a subsequent MRI Prostate (Multiparametric)-targeted biopsy, which is also rated Usually Appropriate. Staging studies like bone scans or PET/CT are Usually Not Appropriate in this initial diagnostic phase, as the risk of metastatic disease is very low before a definitive cancer diagnosis and risk stratification.

In patients with clinically established low-risk prostate cancer on active surveillance, the recommendations mirror those for initial diagnosis. Periodic MRI of the pelvis (with or without contrast) is Usually Appropriate to monitor for changes in tumor size or characteristics that might signal disease progression and the need for definitive treatment. Confirmatory biopsies, either TRUS-guided or MRI-targeted, are also Usually Appropriate at defined intervals.

For patients with clinically established intermediate-risk prostate cancer requiring staging, the imaging strategy expands. Local staging with MRI pelvis without and with IV contrast remains Usually Appropriate. However, to evaluate for metastatic disease, systemic imaging may be indicated. PSMA PET/CT and Fluciclovine PET/CT are now considered Usually Appropriate for staging, along with conventional imaging like CT of the abdomen and pelvis with IV contrast. A whole-body bone scan May be Appropriate in this group.

When staging clinically established high-risk prostate cancer, a comprehensive evaluation for both local and distant disease is critical. MRI of the pelvis (with or without contrast) is Usually Appropriate for assessing local extent (T-staging). For detecting distant metastases, multiple modalities are rated Usually Appropriate, including PSMA PET/CT, Bone scan whole body, and CT of the chest, abdomen, and pelvis with IV contrast. These studies are essential for identifying nodal and osseous metastases that would significantly alter treatment planning. For CT imaging, a standard institutional protocol, such as a CT Abdomen/Pelvis Without Contrast (Renal Stone) protocol, can be adapted with contrast for this purpose.

ACR Imaging Recommendations Table

Adult vs. Pediatric Pretreatment Detection, Surveillance, and Staging of Prostate Cancer Imaging: Radiation Dose Tradeoffs

Prostate cancer is exceedingly rare in the pediatric population, and these ACR guidelines are primarily intended for adult patients. However, the inclusion of pediatric relative radiation levels (RRLs) underscores a universal principle of medical imaging: As Low As Reasonably Achievable (ALARA). For any given radiation dose in millisieverts (mSv), the corresponding pediatric RRL symbol is often higher than the adult one. This reflects the increased radiosensitivity of developing tissues and the longer potential lifespan over which the risks of radiation-induced malignancy can manifest.

In the rare instance that a pediatric or adolescent patient requires evaluation for a pelvic malignancy, non-ionizing modalities like MRI and ultrasound are strongly preferred. For prostate cancer evaluation, MRI is the dominant modality and carries no radiation dose (O 0 mSv), making it equally safe from a radiation standpoint in all age groups. When CT or nuclear medicine studies are unavoidable, protocols should be specifically tailored to the pediatric patient to minimize radiation exposure without compromising diagnostic quality.

Imaging Protocol Details for Pretreatment Detection, Surveillance, and Staging of Prostate Cancer

Once you’ve decided on the right study based on the clinical scenario, ensuring it is performed correctly is the next critical step. The technical parameters of an imaging study—such as MRI sequences or CT contrast timing—are vital for diagnostic accuracy. Our protocol guides provide detailed, scannable information on technique, contrast administration, and interpretation principles for key studies recommended in these guidelines.

• MRI Prostate (Multiparametric)
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex, especially when dealing with nuanced clinical variants. GigHz offers a suite of free reference tools designed to support evidence-based clinical decision-making at the point of care.

For scenarios beyond prostate cancer, the ACR Appropriateness Criteria Lookup tool provides a searchable interface to the full library of ACR guidelines, covering thousands of clinical variants across all organ systems. This helps you quickly find the right imaging test for virtually any clinical presentation.

To ensure the selected study is performed to the highest standard, the Imaging Protocol Library offers detailed, institution-agnostic protocols for hundreds of common and advanced imaging procedures. These guides are invaluable for radiologists, trainees, and technologists aiming to standardize and optimize image acquisition.

When discussing studies that involve ionizing radiation with patients, the Radiation Dose Calculator is a useful aid. It helps estimate effective dose for various exams and can be used to track cumulative exposure, facilitating informed conversations about the risks and benefits of imaging.

Why is multiparametric MRI (mpMRI) the primary imaging tool for initial detection and surveillance?

Multiparametric MRI offers superior soft-tissue contrast compared to other modalities, allowing it to visualize and characterize suspicious lesions within the prostate gland based on cellularity (Diffusion-Weighted Imaging) and vascularity (Dynamic Contrast Enhancement). This capability helps differentiate clinically significant cancers from benign conditions or low-grade tumors. Importantly, MRI does not use ionizing radiation, making it ideal for initial diagnosis and for repeated use in active surveillance protocols.

When is PSMA PET/CT indicated for the initial staging of prostate cancer?

Prostate-Specific Membrane Antigen (PSMA) PET/CT is a highly sensitive and specific imaging modality for detecting metastatic prostate cancer. According to the ACR criteria, it is considered Usually Appropriate for the initial staging of men with newly diagnosed intermediate-risk (particularly unfavorable intermediate-risk) and high-risk prostate cancer. It is rated Usually Not Appropriate for initial diagnosis in biopsy-naïve patients or for staging low-risk disease, where the likelihood of metastases is very low and the test would not change management.

Is a bone scan still needed if a PSMA PET/CT is performed for staging high-risk disease?

While a conventional technetium-99m bone scan is still rated Usually Appropriate for staging high-risk prostate cancer, multiple studies have shown that PSMA PET/CT is more accurate for detecting osseous metastases. Most modern guidelines and clinical practices are shifting towards using PSMA PET/CT as the single, preferred modality for staging high-risk disease, as it can simultaneously evaluate for nodal, visceral, and bone metastases, often with higher sensitivity than the combination of a CT and bone scan. Ordering both is typically redundant.

What is the role of a standard CT scan in prostate cancer staging?

A contrast-enhanced CT of the abdomen and pelvis is rated Usually Appropriate for staging intermediate- and high-risk prostate cancer. Its primary role is to assess for pelvic and retroperitoneal lymph node enlargement (nodal staging) and to detect visceral metastases, particularly in the liver or lungs (if the chest is included). However, CT has limited sensitivity for detecting cancer within the prostate itself (T-staging) and is less sensitive than PSMA PET/CT or a bone scan for osseous metastases. It is considered a well-established, widely available tool for baseline staging.

Why are most imaging studies rated ‘Usually Not Appropriate’ for low-risk prostate cancer?

For patients with low-risk, organ-confined prostate cancer (e.g., low PSA, low Gleason score, small tumor volume), the probability of metastatic disease at diagnosis is extremely low. Therefore, extensive staging with systemic imaging like a bone scan, CT, or PET/CT is not recommended because the potential harms (radiation exposure, cost, false positives leading to further workup) far outweigh the very small chance of finding a true positive result. The focus in this population is on local characterization with MRI and management with active surveillance or definitive local therapy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026